CDK4 and small cell lung carcinoma: These myeloid-protective effects are consistent with previous reports on trilaciclib in SCLC [7, 30], suggesting that CDK4 inhibition alone is sufficient to accelerate haematologic recovery following chemotherapy, achieving comparable outcomes to dual CDK4/6 inhibitors.